ZTTA, a postproline cleaving enzyme inhibitor, improves cerebral ischemia-induced deficits in a three-panel runway task in rats

Pharmacology Biochemistry and Behavior

Volumn 55, Issue 3, 1996, Pages 333-338

  Shishido, Yoshiyuki ^a   Furushiro, Masayoshi ^a   Tanabe, Shuichi ^a   Nishiyama, Saori ^a   Hashimoto, Shusuke ^a   Ohno, Masuo ^b   Yamamoto, Tsuneyuki ^b   Watanabe, Shigenori ^b  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cerebral ischemia; Postproline cleaving enzyme (PPCE); Prolyl endopeptidase; Runway task; Working memory; ZTTA

Indexed keywords

BRAIN ENZYME; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENANTIOMER; ENZYME INHIBITION; ERROR; MALE; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVIEW; TASK PERFORMANCE; WORKING MEMORY;

ANIMALIA;

EID: 0030297239     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00102-5     Document Type: Article

References (52)

1. 1. Aoyagi, T.; Wada, T.; Nagai, M.; Kojima, F.; Harada, S.; Takeuchi, T.; Takahashi, H.; Hirokawa, K.; Tsumita, T. Deficiency of Kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 46:94-97; 1990.
2. 2+ antagonist is neuroprotective in two models of cerebral ischemia. Neuropharmacology 32:1249-1257; 1993.
3. 3. Burbach, J. P. H.; Kovacs, G. L.; De Wied, D. A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. Science 1:1310-1312; 1983.
4. 7] AVP on learning and memory processes in rats with experimental amnesia. Pol. J. Pharmacol. 45:11-22; 1993.
5. 5. Cummings, J. L.; Tomiyasu, U.; Read, S.; Benson, D. F. Amnesia with hippocampal lesions after cardiopulmonary arrest. Neurology 34:679-681; 1984.
6. 6. De Wied, D. Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments. Life Sci. 19:685-690; 1976.
7. 7. Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 55:170-171; 1953.
8. 8. Farkas, R. H.; Nakajima, S.; Nakajima, Y. Neurotensin excites basal forebrain cholinergic neurons: Ionic acid signal-transduction mechanism. Proc. Natl. Acad. Sci. USA 91:2853-2857; 1994.
9. 9. Flexner, J. B.; Flexner, L. B.; Hoffman, P. L.; Walter, R. Doseresponse relationship in attenuation of puromycin-induced amnesia by neurohypophysical peptides. Brain Res. 134:139-144; 1977.
10. 10. Furuya, Y.; Yamamoto, T.; Yatsugi, S.; Ueki, S. A new method for studying working memory by using the three-panel runway apparatus in rats. Jpn. J. Pharmacol. 46:183-188; 1988.
11. 11. Gibson, G. E.; Blass, J. P. Impaired synthesis of acetylcholine in brain accompanying mild hypoxia and hypoglycemia. J. Neurochem. 27:37-42; 1976.
12. 12. Goto, K.; Ishige, A.; Sekiguchi, K.; Iizuka, S.; Sugimoto, A.; Yuzurihara, M.; Aburada, M.; Hosoya, E.; Kogure, K. Effects of cycloheximide on delayed neuronal death in rat hippocampus. Brain Res. 534:299-302; 1990.
13. 13. Horita, A.; Carino, M. A.; Lai, H. Pharmacology of thyrotropin-releasing hormone. Annu. Rev. Pharmacol. Toxicol. 26:311-332; 1986.
14. 14. Horita, A.; Carino, M. A.; Zabawska, J.; Lai, H. TRH analogue MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides 10:121-124; 1989.
15. 15. Hossmann, K. A.; Lechtape-Gruter, H.; Hossmann, V. The role of cerebral blood flow for the recovery of the brain after prolonged ischemia. J. Neurol. 204:281-299; 1973.
16. 16. Kakihana, M.; Yamazaki, N.; Nagaoka, A. Effects of idebenone (CV-2619) on the concentrations of acetylcholine and choline in various brain regions of rats with cerebral ischemia. Jpn. J. Pharmacol. 36:357-363; 1984.
17. 17. Kamei, H; Ueki, T.; Obi, Y.; Fukagawa, Y; Oki, T. Protective effect of Eurystatins A and B, new prolyl endopeptidase inhibitors, on scopolamine-induced amnesia in rats. Jpn. J. Pharmacol. 60:377-380; 1992.
18. 18. Kaneko, T.; Wood, G.; Crouch, W. L.; Desiderio, D. M. Substance P inactivating enzymes in human cerebrospinal fluid. Peptides 15:41-47; 1994.
19. 19. Kano, T.; Katayama, Y.; Miyazaki, S.; Kinoshita, K.; Kawamata, T.; Tsubokawa, T. Effects of indeloxazine on hippocampal CA1 pyramidal cell damage following transient cerebral ischemia in the gerbil. Neuropharmacology 32:307-310; 1993.
20. 20. Kirino, T.; Tamura, A.; Sano, K. Selective vulnerability of the hippocampus to ischemia-reversible and irreversible types of ischemic cell damage. In: Kogure, K.; Hossmann, K.-A.; Siesjo, B. K.; Welsh, F. A., eds. Molecular mechanisms of ischemic brain damage, vol. 63. Progress in brain research. Amsterdam: Elsevier; 1985:39-58.
21. 21. Kiyota, Y.; Miyamoto, M.; Nagano, A. Relationship between brain damage and memory impairment in rats exposed to transient forebrain ischemia. Brain Res. 538:295-302; 1991.
22. 22. Kodama, K.; Shibata, S.; Ueki, S. Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn. J. Pharmacol. 60:33-38; 1992.
23. 23. Koob, G. F.; Lebrun, C.; Bluthe, R. M.; Dantzer, R.; Le Moal, M. Role of neuropeptides in learning vs. performance: focus on vasopressin. Brain Res. Bull. 23:359-264; 1989.
24. 24. Kovacs, G. L.; Buijs, R. M.; Bohus, B.; Van Wimersma Greidanus, T. Microinjection of arginine8-vasopressin antiserum into the dorsal hippocampus attenuates passive avoidance behavior in rats. Physiol. Behav. 28:45-48; 1982.
25. 25. Kowall, N. W.; Bealk, N. F.; Busciglio, J.; Duffy, L. K.; Yankner, B. A. An in vivo model for the neurodegenerative effects of β-amyloid and protection by substance P. Proc. Natl. Acad. Sci. USA 88:7247-7251; 1991.
26. 26. Kubota, A.; Nakajima, T.; Okada, T.; Hayashi, T.; Nakamura, K. A new nootropic aniracetam: Its prevention of scopolamine-induced retrograde amnesia and its possible action mechanism. Jpn. J. Pharmacol. Suppl. 33:67p: 1983.
27. 27. Maegawa, H.; Katsube, N.; Okegawa, T.; Aishita, H.; Kawasaki, A. Arginine-vasopressin fragment 4-9 stimulates the acetylcholine release in hippomacpus of freely moving rats. Life Sci. 51:285-293; 1992.
28. 28. Mellow, A. M.; Sunderland, T.; Cohen, R. M.; Lawlor, B. A.; Hill, J. L.; Newhouse, P. A.; Cohen, M. R.; Murphy, D. L. Acute effects of high-dose thyrotropin-releasing hormone infusions in Alzheimer's disease. Commun. Psychopharmacol. 98:403-407; 1989.
29. 29. Miyamoto, M.; Hirai, K.; Takahashi, H.; Kato, K.; Nishiyama, M.; Okada, H.; Nagaoka, A. Effects of sustained release formulation of thyrotropin-releasing hormone on learning impairments caused by scopolamine and AF64A in rodents. Eur. J. Pharmacol. 238:181-189; 1993.
30. 30. Nakajima, T.; Ono, Y.; Kato, A.; Maeda, J.; Ohe, T. Y29794 - A nonpeptide prolyl endopeptidase inhibitor that can penetrate into the brain. Neurosci. Lett. 141:156-160; 1992.
31. 31. Ogawa, N.; Haba, K.; Yoshikawa, H.; Ono, T.; Mizukawa, K. Comparison of the effects of bifemelane hydrochloride, idebenone and indeloxazine hydrochloride on ischemia-induced depletion of brain acetylcholine levels in gerbil. Res. Commun. Chem. Pathol. Pharmacol. 61:285-288; 1988.
32. 32. Ohno, M.; Yamamoto, T.; Kitajima, I.; Ueki, S. WEB 1881FU ameliorates impairment of working memory induced by scopolamine and cerebral ischemia in the three-panel runway task. Jpn. J. Pharmacol. 54:53-60; 1990.
33. 33. Ohno, M.; Yamamoto, T.; Ueki, S. Effect of the κ-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task. Eur. J. Pharmacol. 193:357-361; 1991.
34. 34. Ohno, M.; Yamamoto, T.; Watanabe, S. Effect of staurosporine, a protein kinase C inhibitor, on impairment of working memory in rats exposed to cerebral ischemia. Eur. J. Pharmacol. 204:113-116; 1991.
35. 35. Ohno, M.; Yamamoto, T.; Ueki, S.; Watanabe, S. Protection by N-methyl-D-aspartate receptor antagonists against impairment of working memory in rats following transient cerebral ischemia. Neurosci. Lett. 138:1-4; 1992.
36. 36. Pulsinelli, W. A.; Brierley, J. B. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 10:267-272; 1979.
37. 37. Renaud, L. P.; Blume, H. W.; Pittman, Q. J.; Lamour, Y.; Tan, A. T. Thyrotropin-releasing hormone selectively depresses glutamate excitation of cerebral cortical neurons. Science 205:1275-1276; 1979.
38. 38. Schmidt, D. E. Effects of thyrotropine releasing hormone (TRH) on pentobarbital-induced decrease in cholinergic neuronal activity. Commun. Psychopharmacol. 1:469-473; 1977.
39. 39. Scremin, A. M. E.; Scremin, O. U. Physostigmine-induced cerebral protection against hypoxia. Stroke 10:142-143; 1979.
40. 40. Shibata, S.; Kodama, K.; Tominaga, K.; Tanaka, T.; Watanabe, S. Effect of muscarinic cholinergic drugs on ischemia-induced decreases in glucose uptake and CA1 field potentials in rat hippocampal slices. Eur. J. Pharmacol. 221:113-119; 1992.
41. 2 receptor antagonists. Eur. J. Pharmacol. 229:21-29; 1992.
42. 42. Tanaka, K.; Ogawa, N.; Mizukawa, K.; Asanuma, M.; Kondo, Y.; Nishibayashi, S.; Mori, A. Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and post-synaptic cholinergic indices in the gerbil brain following transient ischemia. Neurochem. Res. 19:117-122; 1994.
43. 43. Tate, S. S. Purification and properties of a bovine brain thyrotropin-releasing factor deamidase - A postproline cleaving enzyme of limited specificity. Eur. J. Pharmacol. 118:17-23; 1981.
44. 44. Toide, K.; Shinoda, M.; Takase, M.; Iwata, K.; Yoshida, H. Effects of a novel thyrotropin-releasing hormone analogue, JTP-2942, on extracellular acetylcholine and choline levels in the rat frontal cortex and hippocampus. Eur. J. Pharmacol. 233:21-28; 1993.
45. 45. Valentino, K.; Newcomb, R.; Gadbois, T.; Singh, T.; Bowersox, S.; Bitner, S.; Justice, A.; Yamashiro, D.; Huffman, B. B.; Ciaranello, R.; et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. USA 90:7894-7897; 1993.
46. 46. Yamamoto, M.; Shimizu, M. Effects of a new TRH analogue, YM-14673 on the central nervous system. Naunyn Schmiedebergs Arch. Pharmacol. 336:561-565; 1987.
47. 47. Yamamoto, M.; Shimizu, M. Effects of a new TRH analogue, YM-14673 on a passive avoidance test as a possible criterion of improvement in cognitive distubance in rodents. Naunyn Schmiedebergs Arch. Pharmacol. 338:262-267; 1988.
48. 48. Yoshimoto, T.; Ogita, K.; Walter, M.; Koida, M.; Tsuru, D. Postproline cleaving enzyme. Biochim. Biophys. Acta 569:184-192: 1979.
49. 49. Yoshimoto, T.; Simmons, W. H.; Kita, T.; Tsuru, D. Postproline cleaving enzyme from lamb brain. J. Biochem. 90:325-334; 1981.
50. 50. Yoshimoto, T.; Nishimura, T.; Kita, T.; Tsuru, D. Postproline cleaving enzyme (prolyl endopeptidase) from bovine brain. J. Biochem. 94:1179-1190; 1983.
51. 51. Yoshimoto, T.; Kado, K.; Matsubara, F.; Koriyama, N.; Kaneto, H.; Tsuru, D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J. Pharmacobiodyn. 10:730-735; 1987.
52. 52. Zola-Morgan, S.; Squire, L. R.; Amaral, D. G. Human amnesia and the medial temporal region: Enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J. Neurosci. 6:2950-2967; 1986.